Acute and severe acne in a patient treated with Bevacizumab

International Journal of Dermatology

Volumn 52, Issue 4, 2013, Pages 486-490

  Molina Ruiz, Ana María ^a   Domine, Manuel ^a   Requena, Luis ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CLINDAMYCIN; DOCETAXEL; DOXYCYCLINE; ERLOTINIB;

ACNE; ADULT; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; COMEDO; DISEASE COURSE; DRUG INDUCED DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PAPULE; PHYSICAL EXAMINATION; PUSTULE; SKIN BIOPSY; TREATMENT RESPONSE;

ACNE VULGARIS; ACUTE DISEASE; ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; DRUG ERUPTIONS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 84875064064     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2012.5658.x     Document Type: Article

References (20)

1. Wozel G, Sticherling M, Schön MP. Cutaneous side-effects of inhibition of VEGF signal transduction. J Dtsch Dermatol Ges 2010; 8: 243-249.
2. Keenan BP, Abuav R. Acneiform eruption in a patient receiving bevacizumab for glioblastoma multiforme. Arch Dermatol 2010; 146: 577.
3. Gotlib V, Khaled S, Lapko I, et al. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs 2006; 17: 1227-1229.
4. Saif MW, Longo WL, Israel G. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer. Clin Colorectal Cancer 2008; 7: 144-148.
5. Amselem L, Diaz-Llopis M, Garcia-Delpech S, et al. Papulopustular eruption after intravitreal bevacizumab (Avastin). Acta Ophthalmol 2009; 87: 110-111.
6. Ladas ID, Moschos MM, Papakostas TD, et al. Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization. Clin Ophthalmol 2009; 3: 129-131.
7. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal revascularization associated with pathological myopia. Br J Ophthalmol 2007; 91: 161-165.
8. Adams BB, Mutasim DF. Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasizing melanoma. J Cancer Res Clin Oncol 2007; 133: 897-901.
9. Scarlato M, Previtali SC. POEMS syndrome: the matter-of-fact approach. Curr Opin Neurol 2011; 24: 491-496.
10. Caye L, Scheid K, Pizzol MM, et al. Use of bevacizumab (Avastin) in KID syndrome. Arq Bras Oftalmol 2010; 73: 285-290.
11. Smith AR, Hennessy JM, Kurth MA, et al. Reversible skeletal changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndrome. Pediatr Blood Cancer 2008; 51: 418-420.
12. Shord SS, Bressler LR, Tierney LA, et al. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm 2009; 66: 999-1013.
13. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
14. Vihinen P, Paija O, Kivisaari A, et al. Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case report. J Med Case Reports 2011; 5: 243-246.
15. Ruiz V, Garcia-Muret MP, Alomar A. Hand eruption after intravenous administration of bevacizumab. J Eur Acad Dermatol Venereol 2011; 25: 238-239.
16. Black JM, Hodari KT, Rogers N, et al. Exudative, non-healing scalp: a complication of systemic chemotherapy with capecitabine and bevacizumab. Arch Dermatol 2011; 147: 134-135.
17. Vaño-Galvan S, Moreno C, Medina J, et al. Perforating dermatosis in a patient receiving bevacizumab. J Eur Acad Dermatol Venereol 2009; 23: 972-974.
18. Fourcade S, Gaudy-Marqueste C, Tasei AM, et al. Localized skin necrosis of steroid-induced striae distensae: an unusual complication of bevacizumab and irinotecan therapy. Arch Dermatol 2011; 147: 1227-1228.
19. DeWitt CA, Siroy AE, Stone SP. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol 2007; 56: 500-505.
20. Man XY, Yang XH, Cai SQ, et al. Expression and localization of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 in human epidermal appendages: a comparison study by immunofluorescence. Clin Exp Dermatol 2009; 34: 396-401.